Is Post Operative Radiotherapy Justified for Completely Resected Locally Advanced Renal Cell Cancers?


Background: There is an underutilization of postoperative radiation therapy (PORT) in renal cell carcinoma (RCC) following radical nephrectomy (RN). The main reason for that is the lack of strong evidence and the contradictory data in the literature regarding its benefit. We aimed to evaluate the efficacy of PORT in locally advanced patients with RCC following complete resection. Materials and Methods: The patients had RN and at least two of the poor prognostic factors like lymph nodes involvement (LN+), renal vein invasion (RVI), inferior vena cava invasion (IVCI) and renal capsule infiltration (RCI) were included in the study. Ninety-four patients were retrospectively evaluated; 56 patient received PORT 50Gy/25 fractions/5 weeks and 38 patients who did not receive PORT were compared. The LN+, RVI, IVCI and RCI were documented in 63 (67%), 46 (49%), 30 (32%) and 71 (76%) patients respectively. Results: Eight patients (14%) in PORT arm developed local recurrence (LR) are compared with 10 patients (26%) for non-PORT arm. Five-year overall survival (OS) rates were 78% and 70% for PORT and non-PORT arms respectively (p = 0.3), while 5-year locoregional control (LRC) rates were 88% for PORT arm and 70% for the non-PORT arm (p = 0.05). The IVCI and LN+ affected OS significantly (p values 0.007 and 0.009) respectively. The RCI and LN+ only affected the LRC with p values 0.03, 0.04 respectively. Two out of 56 patients (3.5%) received PORT developed intestinal obstruction which was treated surgically. Conclusion: The PORT decreased the LR rate in high risk locally advanced RCC patients significantly. The high incidence of distant metastasis offsets this improvement at the level of overall survival.

Share and Cite:

R. Abdulmoniem, T. Haikal and H. Darwiesh, "Is Post Operative Radiotherapy Justified for Completely Resected Locally Advanced Renal Cell Cancers?," Journal of Cancer Therapy, Vol. 4 No. 9, 2013, pp. 1429-1434. doi: 10.4236/jct.2013.49170.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] W. H. Chow, S. S. Devesa, J. L. Warren and J. F. Fraumeni Jr., “Rising Incidence of Renal Cell Cancer in the United States,” JAMA, Vol. 281, No. 17, 1999, pp. 1628-1631. jama.281.17.1628
[2] A. Jemal, R. Siegel, E. Ward, et al., “Cancer Statistics 2008,” CA Cancer Journal for Clinicians, Vol. 58, No. 2, 2008, pp. 71-96.
[3] J. Pantuck, A. Zisman and A. Bellderun, “The Changing Natural History of Renal Cell Carcinoma,” The Journal of Urology, Vol. 166, No. 5, 2001, pp. 1611-1623. (05)65640-6
[4] I. Aref, G. Bociek and D. Salhani, “Is Postoperative Radiotherapy for Renal Cell Carcinoma Justified?” Radiotherapy & Oncology, Vol. 43, No. 2, 1997, pp. 155-157. (97)01949-X
[5] A. P. Sene, R. F. T. Hunt, T. McMahon and R. N. P. Carol, “Renal Carcinoma in Patients Undergoing Nephrectomy: Analysis of Survival and Prognostic Factors,” British Journal of Urology, Vol. 70, No. 2, 1992, pp. 125-134.
[6] R. A. Rabinovitch, M. J. Zelefsky, J. J. Gaynor and Z. Fuks, “Patterns of Failure Following Surgical Resection of Renal Cell Carcinoma: Implications for Adjuvant Local and Systemic Therapy,” Journal of Clinical Oncology, Vol. 12, 1994, pp. 206-212.
[7] A. Safwat, T. Shouman and E. Hamada, “Postoperative Radiotherapy Improves Disease Free but Not Overall Survival in High Risk Cell Carcinoma Patients,” Journal of the Egyptian National Cancer Institute, Vol. 12, 2000, pp. 17-22.
[8] M. Stein, A. Kuten, J. Halperin, N. M. Coachman, Y. Cohen and E. Robinson, “The Value of Postoperative in Renal Cell Cancer,” Radiotherapy and Oncology, Vol. 24, No. 1, 1992, pp. 41-45.
[9] M. Eilenberger, R. Kodyam and R. Seyess, “A Retrospective Study of the Results of Postoperative Radiotherapy of Hypernephroma,” Radiobiologia, Radiotherapia (Berlin), Vol. 31, 1990, pp. 491-496.
[10] E. Scherer and C. Wirtz, “The Role of Postoperative Radiotherapy in the Treatment of Hypernephroid Carcinoma,” Strahlentherapie und Onkologie, Vol. 164, 1988, pp. 371-385.
[11] M. Kjaer, P. L. Frederiksen and S. A. Engelholm, “Postoperative Radiotherapy in Stage II and III Renal Adenocarcinoma. A Randomized Trial by the Copenhagen Renal Cancer Study Group,” International Journal of Radiation Oncology & Biology & Physics, Vol. 13, No. 5, 1987, pp. 665-672.
[12] M. Kjaer, P. Iversen, V. Hvidt, E. Bruun, P. Skaarup, H. J. Bech and P. L. Frederiksen, “A Randomized Trial of Postoperative Radiotherapy versus Observation in Stage II and III Renal Adenocarcinoma. A Study by the Copenhagen Renal Cancer Study Group,” Scandinavian Journal of Urology, Vol. 21, No. 4, 1987, pp. 285-289.
[13] M. A. Tunio, A. Hashmi and M. Rafi, “Need for New Trial to Evaluate PORT in Renal Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials,” Annals of Oncology, Vol. 21, No. 9, 2010, pp. 1839-1845.
[14] U. Cuneyt, A. Gorkem, F. Merdan, O. Kuzhan, L. Tahmaz and M. Beyzadeoglu, “The Value of Postoperative Radiotherapy in Renal Cell Carcinoma: A Single Institution Experience,” Tumori, Vol. 92, 2006, pp. 202-206.
[15] S. Rafla, “Renal Cell Carcinoma,” Cancer, Vol. 25, 1970, pp. 26-40.<26::AID-CNCR2820250106>3.0.CO;2-4
[16] S. Rafla and K. Parikh, “The Role of Adjuvant Radiotherapy in the Management of Renal Cell Carcinoma,” In: N. Javadpour, Ed., Cancer of the Kidney, Thieme-Stratton, New York, 1984, p. 231.
[17] R. Makarewicz, M. Zarzycka, G. Kulinska and W. Windorbska, “The Value of Postoperative Radiotherapy in Advanced Renal Cell Cancer,” Neoplasma, Vol. 45, 1998, pp. 380-383.
[18] E. Gez, M. Libes, R. Bar-Deroma, R. Rubinov, M. Stein and A. Kuten, “Postoperative Irradiation in Localized Renal Cell Carcinoma: The Rambam Medical Center Experience,” Tumori, Vol. 88, 2002, pp. 500-502.
[19] R. Finney, “An Evaluation of Postoperative Radiotherapy in Hypernephroma Treatment—A Clinical Trial,” Cancer, Vol. 32, No. 6, 1973, pp. 1332-1340. 32:6<1332::AID-CNCR2820320607>3.0.CO;2-E

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.